In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
In the UK DANTE trial stopping immunotherapy at 12 months produces disease control rates comparable to two-year treatment …
U.S. regulators expand treatment options in prostate cancer as biotech innovators TRexBio and Spinogenix push forward with immune …
New pivotal trial milestones in multiple sclerosis and head and neck cancer, plus key collaboration and funding moves, …
Landmark ATOMIC trial shows combining immunotherapy and chemo improves outcomes for colon cancer patients with mismatch-repair deficiency
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Results from the Sunrise-1 trial suggest a new option for patients with second-line papillary non-muscle invasive bladder cancer
New data from India suggest that Hillchol, an oral cholera vaccine by Bharat Biotech, is safe, effective and …
Early-phase trial data for a theranostic radiopharmaceutical, 177Lu-NeoB, demonstrate safety and potential tumour control in patients with GRPR-positive …
Phase III SEQUOIA-HCM analyses show aficamten offers benefit to patients with varying symptom severity and across regions, opening …
In May 2025, a gene therapy for Rett syndrome has cleared major regulatory design review and is activating …
Already a subscriber? Log in